EPO and Recurrent upper respiratory tract infections: Events occurring in a notably greater proportion of erythropoietin-treated patients than erythropoietin-naïve patients were fatigue (47% vs. 33%), anaemia (16% vs. 7%) and upper respiratory tract infection (15% vs. 4%).